Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors during the central anxious system, conolidine modulates alternate molecular targets. A Science Advances review uncovered that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://210list.com/story21518016/fascination-about-conolidin-to-replace-traditional-painkillers